Nephrology

Back to articles

Few advantages proven for a particular phosphate binder in patients with kidney disease

KEY POINT

As assessment of sevelamer (Renvela—Genzyme) and lanthanum (Fosrenol—Shire) compared with calcium-containing and iron-based phosphate binders in patients with chronic kidney disease (CKD) revealed few clinically important advantages for any agent, according to results of an extensive systematic review and meta-analysis published online in Nephrology Dialysis Transplantation.